HRT effects on inflammatory markers: Is chronic inflammation a contra-indication for HRT?

International Congress Series

Volumn 1229, Issue C, 2002, Pages 103-108

  Kluft, C ^a  

^a TNO   (Netherlands)

Author keywords

CRP; Haemostasis; HRT; Inflammation; Oestrogen; Vascular wall

Indexed keywords

EID: 0005065498     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00469-1     Document Type: Article

References (26)

1. H.E. Brussaard J.A. Gevers Leuven M. Frolich C. Kluft H.M.J. Krans Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM Diabetologia 40 1997 843 849
2. A. Von Clauss Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens Acta Haematol. 17 1957 231 237
3. G. Avvisati J.W. ten Cate E.M. van Wijk L.H. Kahle G. Mariani Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment Br. J. Haematol. 45 1980 343 352
4. M. Ranby N. Bergsdorf T. Nilsson G. Mellbring B. Winblad G. Bucht Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay Clin. Chem. 32 1986 2160 2165
5. P. Meijer D.E. Pollet J. Wauters C. Kluft Specificity of antigen assays of plasminogen activator inhibitor in plasma: innotest PAI-1 immunoassay evaluated Clin. Chem. 40 1994 110 115
6. K.K. Koh M.N. Bui R. Mincemoyer R.O. Cannon Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women Am. J. Cardiol. 80 1997 1505 1507
7. K.K. Koh A. Blum L. Hathaway R. Mincemoyer G. Csako M.A. Waclawiw J.A. Panza R.O. Cannon Vascular effects of estrogen and vitamin E therapy in postmenopausal women Circulation 100 1999 1851 1857
8. T. Caulin-Glazer W.J. Farrell S.E. Pfau B. Zaret K. Bunger J.F. Setaro J.J. Brennan J.R. Bender M.W. Cleman H.S. Cabin M.S. Remetz Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease J. Am. Coll. Cardiol. 31 1998 1555 1560
9. W.M. Van Baal P. Kenemans J.J. Emeis C.G. Schalkwijk V. Mijatovic M.J. van der Mooren U.M. Vischer C.D. Stehouwer Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women Fertil. Steril. 71 1999 663 670
10. S.C. Lim A.E. Caballero S. Arora P. Smakowski E.M. Bashoff F.M. Brown F.W. Logerfo E.S. Horton A. Veves The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes J. Clin. Endocrinol. Metab. 84 1999 4159 4164
11. W.M. Van Baal J.J. Emeis P. Kenemans H. Kessel E.R. Peters-Muller C.G. Schalkwijk M.J. van der Mooren C.D. Stehouwer Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules Eur. J. Clin. Invest. 29 1999 913 921
12. P.Y. Scarabin M. Alhenc-Gelas E. Oger G. Plu-Bureau Hormone replacement therapy and circulating ICAM-1 in postmenopausal women—a randomised controlled trial Thromb. Haemostasis 81 1999 673 675
13. G. Salobir I. Keber I. Seljeflot H. Arnesen L. Vrabic Hormone replacement therapy (HRT) reduces expression of cell adhesion molecules in healthy postmenopausal women Atherosclerosis 151 2000 243 244
14. I. Seljeflot H. Arnesen A.E. Hofstad I. Os Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease Thromb. Haemostasis 83 2000 944 948
15. C. Kluft Pro-inflammatory effects of oestrogens Fibrinolysis Proteolysis 13 1999 217 219
16. A. Nakagomi S.B. Freedman C.L. Geczy Interferon-γ and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment Circulation 101 2000 1785 1791
17. M.P.M. De Maat F. Haverkate C. Kluft C-reactive protein: a cardiovascular risk factor: report on the CRP hot-topic workshop Oct. 1, 1997 Fibrinolysis Proteolysis 12 1998 323 327
18. P.M. Ridker C.H. Hennekens N. Rifai J.E. Buring J.E. Manson Hormone replacement therapy and increased plasma concentration of C-reactive protein Circulation 100 1999 713 716
19. M. Cushman C. Legault E. Barrett-Connor M.L. Stefanick C. Kessler H.L. Judd P.A. Sakkinen R.P. Tracy Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal Estrogen/Progestin Interventions (PEPI) Study Circulation 100 1999 717 722
20. M.W. Van Baal P. Kenemans M.J. Vander Mooren H. Kessel J.J. Emeis C.D.A. Stehouwer Increased C-reactive protein level during short-term hormone replacement therapy in healthy postmenopausal women Thromb. Haemostasis 81 1999 925 928
21. De Valk-de Roo C.D.A. Stehouwer P. Meijer V. Mijatovic C. Kluft P. Kenemans F. Cohen S. Watts C. Netelenbos Both Raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study Arterioscler., Thromb., Vasc. Biol. 19 1999 2993 3000
22. M. Frohlich A. Doring A. Imhof W.L. Hutchinson M.B. Pepys W. Koenig Oral contraceptive use is associated with a systematic acute phase response Fibrinolysis Proteolysis 13 2000 239 244
23. F. Bayard Cellular and molecular mechanisms of the atheroprotective effects of estrogens Atherosclerosis 151 2000 167
24. K.S. Channer K.M. English Hormone replacement therapy in postmenopausal women and cardiovascular risk Lancet 353 1999 1528
25. D.B. Petitti Hormone replacement therapy and heart disease prevention. Experimentation trumps observation (editorial) JAMA 280 1998 650 652
26. M. Cushman E.N. Meilahn B.M. Psaty L.H. Kuller A.S. Dobs R.P. Tracy Hormone replacement therapy, inflammation, and hemostasis in elderly women Arterioscler., Thromb., Vasc. Biol. 19 1999 893 899